Browse by author
Lookup NU author(s): Professor John O'Brien, Professor John-Paul TaylorORCiD, Professor David BrooksORCiD, Professor Ian McKeith, Professor Alison Yarnall
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2022, The Author(s).Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.
Author(s): O'Brien JT, Chouliaras L, Sultana J, Taylor J-P, Ballard C, Aarsland D, Blanc F, Boeve B, Brooks DJ, Chaudhuri KR, Cummings J, Feldman HH, Flicker L, Galvin JE, Grosset DG, Ikeda M, Kohlhaas S, Lawlor B, Lemstra AW, Leroi I, Londos E, Leverenz JB, Lewis S, McKeith I, Mills R, Oakley R, Richardson J, Sabbagh M, Skidmore J, Svennigsson P, Tiraboschi P, Weintraub D, Walker Z, Watson R, Weil RS, Williams-Gray CH, Yarnall A
Publication type: Review
Publication status: Published
Journal: Alzheimer's Research and Therapy
Year: 2022
Volume: 14
Issue: 1
Print publication date: 01/12/2022
Online publication date: 11/11/2022
Acceptance date: 17/10/2022
ISSN (electronic): 1758-9193
Publisher: BioMed Central Ltd
URL: https://doi.org/10.1186/s13195-022-01103-7
DOI: 10.1186/s13195-022-01103-7
PubMed id: 36369100
